Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

125.02 -0.18 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,589,891
Open 124.81
Bid (Size) 124.80 (800)
Ask (Size) 126.36 (100)
Prev. Close 125.20
Today's Range 122.50 - 125.64
52wk Range 86.08 - 127.68
Shares Outstanding 1,253,809,440
Dividend Yield 2.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Healthcare Stock to Own for Decades and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks

Performance

YTD
+36.1%
+36.1%
1 Month
+5.5%
+5.5%
3 Month
+5.0%
+5.0%
6 Month
+24.6%
+24.6%
1 Year
+35.0%
+35.0%

More News

Read More
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
Via Stocktwits
News headline image
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV ↗
Via Stocktwits
News headline image
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial ↗
Via Benzinga
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
2 Supercharged Dividend Stocks to Buy Now ↗
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Is the AI Rally a Bubble? Impact on Commodity Demand and Defensive Stock Rotation
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals
Via 24-7 Press Release
News headline image
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend ↗
Via Benzinga
News headline image
Gilead Provides Update on Phase 3 ASCENT-07 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
3 Cash-Rich Stocks With High Growth Potential Right Now ↗
Via MarketBeat
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Appears as a Decent Value Stock ↗
Via Chartmill
News headline image
Moderna Earnings: What To Look For From MRNA
Via StockStory
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 125.02
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 11/14/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 156.75B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 157B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.